...
首页> 外文期刊>Angewandte Chemie >Molecular Alliance—From Orthosteric and Allosteric Ligands to Dualsteric/Bitopic Agonists at G Protein Coupled Receptors
【24h】

Molecular Alliance—From Orthosteric and Allosteric Ligands to Dualsteric/Bitopic Agonists at G Protein Coupled Receptors

机译:分子联盟—从正构和变构配体到G蛋白偶联受体的双位/双位激动剂

获取原文
获取原文并翻译 | 示例
           

摘要

Cell-membrane-spanning G protein coupled receptors (GPCRs) belong to the most important therapeutic target structures. Endogenous transmitters bind from the outer side of the membrane to the "orthosteric" binding site either deep in the binding pocket or at the extracellular N-terminal end of the receptor protein. Exogenous modulators that utilize a different, "allosteric", binding site unveil a pathway to receptor subtype-selectivity. However, receptor activation through the orthosteric area is often more powerful. Recently there has been evidence that orthosteric/allosteric, in other words "dualsteric", hybrid compounds unite subtype selectivity and receptor activation. These "bitopic" modulators channelreceptor activation and subsequent intracellular signaling into a subset of possible routes. This concept offers access to GPCR modulators with an unprecedented receptor-subtype and signaling selectivity profile and, as a consequence, to drugs with fewer side effects.
机译:细胞膜跨膜G蛋白偶联受体(GPCR)属于最重要的治疗靶标结构。内源性递质从膜的外侧结合到受体蛋白深处的结合口袋中或细胞外N-末端的“正构”结合位点。利用不同的“变构”结合位点的外源性调节剂揭示了一条通往受体亚型选择性的途径。但是,通过正位区的受体激活通常更有效。最近,有证据表明正构/变构,换句话说是“双构”,杂合化合物将亚型选择性和受体活化结合在一起。这些“双向”调节剂将受体激活和随后的细胞内信号传导转变为可能途径的子集。这一概念使人们能够获得具有前所未有的受体亚型和信号选择性谱的GPCR调节剂,从而获得副作用更少的药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号